THERAVECTYS presents lentiviral vector-based therapeutic vaccine trial results
The trial, which was placebo-controlled and randomized, involved 38 HIV-positive patients. They purpose of the study was to determine the safety, immunogenicity and tolerability of the new vaccine candidate compared to the placebo.
“We are very pleased to present the clinical data of this first-ever lentivector based therapeutic vaccine trial,” Dr. Hélène Toussaint, senior scientist in charge of the HIV vaccine program, said.
The patients received two intramuscular injections with a time distance of eight weeks between them. The injections were completed with non-replicative and self-inactivating lentiviral vectors.
"These data provide further evidence that THERAVECTYS' regimen vaccine is safe and well tolerated, and can induce intense, broad and long-lasting cellular immune responses in vaccinated patients regardless their preexisting immune profile,” Dr. Cécile Bauche, chief scientific officer of the company, said.
The results show the safety and tolerance of the new vaccine. It also suggests that the vaccine is effective.
"The clinical data of this trial supports the potential of the lentiviral vector platform developed by THERAVECTYS for the future development of therapeutic vaccines and immunotherapies in oncology and infectious diseases,” THERAVECTYS CEO Renaud Vaillant said.
The company presented its information this past weekend at the 2015 Towards an HIV Cure Symposium, which will take place in Vancouver, Canada. This conference will be held immediately before the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention, also known as IAS 2015.